Daclizumab-induced encephalitis in multiple sclerosis
Open Access
- 24 September 2019
- journal article
- editorial
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 25 (12), 1557-1559
- https://doi.org/10.1177/1352458519845079
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple SclerosisBiomedicines, 2019
- Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosisMultiple Sclerosis Journal, 2019
- GFAPα IgG-associated encephalitis upon daclizumab treatment of MSNeurology Neuroimmunology & Neuroinflammation, 2018
- DRESS Syndrome and Daclizumab Failure-Were Potentially Dangerous Signs Missed in Clinical Trials?Drug Target Insights, 2018
- Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple SclerosisNeurotherapeutics, 2017
- Regulatory T cells in multiple sclerosis and myasthenia gravisJournal of Neuroinflammation, 2017
- Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studiesMultiple Sclerosis and Related Disorders, 2016
- Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulationProceedings of the National Academy of Sciences of the United States of America, 2016